

# GUIDELINES FOR EMERGENCY MANAGEMENT OF HEMOPHILIA AND VON WILLEBRAND DISEASE

## FactorFirst

**Delay in the restoration of hemostasis to the patient with hemophilia or von Willebrand disease may be life or limb-threatening.**

- **PROMPT TRIAGE AND ASSESSMENT.**

- Determine the severity of the bleed.
- Recognize that bleeding in the head, spine, abdomen or pelvis may initially be occult and potentially life-threatening.

- **TREAT FIRST AND INVESTIGATE LATER – “FACTOR FIRST”.**

- Avoid invasive procedures such as arterial punctures unless the patient has factor replacement.
- **NO** IM injections and **NO** ASA.
- The patient or guardian may be your most important resource, so do ask about specific treatment protocols.
- Contact the patient’s Hemophilia Treatment Centre where a hematologist is always on call.
- Provide clear discharge instructions and arrange a follow-up plan or admit to hospital if necessary.

### **LIFE OR LIMB-THREATENING BLEEDS**

- Head (intracranial) and neck
- Chest, abdomen, pelvis, spine
- Iliopsoas muscle and hip
- Massive vaginal hemorrhage
- Extremity muscle compartments
- Fractures or dislocations
- Any deep laceration
- Any uncontrolled bleeding

### **MODERATE/MINOR BLEEDS**

- Nose (epistaxis)
- Mouth (including gums)
- Joints (hemarthroses)
- Menorrhagia
- Abrasions and superficial lacerations

### **TREATMENT FOR LIFE OR LIMB-THREATENING BLEEDS**

#### **PATIENT MUST RECEIVE PRODUCT URGENTLY**

**Hemophilia A: (all severities)**  
Recombinant factor VIII concentrate 40-50 units/kg

**Hemophilia B: (all severities)**  
Recombinant factor IX concentrate 100-120 units/kg >15 yrs  
Recombinant factor IX concentrate 135-160 units/kg <15 yrs  
The dosage for recombinant factor IX is substantially higher because of its lower recovery, particularly in children.

**Von Willebrand Disease:**  
A VW factor concentrate containing factor VIII such as Humate-P 60-80 Ristocetin cofactor units/kg

**It is critical to raise the factor level to 80-100% urgently for all life or limb-threatening bleeds.**

### **TREATMENT FOR MODERATE/MINOR BLEEDS**

#### **PATIENT MUST RECEIVE PRODUCT WITHIN 30 MINUTES WHENEVER POSSIBLE**

**Hemophilia A: (severe/moderate)**  
Recombinant factor VIII concentrate 20-30 units/kg

**Hemophilia A: (mild)**  
Desmopressin (Octostim/DDAVP) 0.3 mcg/kg (max. 20 mcg) –SC/IV

**Hemophilia B: (severe/moderate/mild)**  
Recombinant factor IX concentrate 35-50 units/kg >15 yrs  
Recombinant factor IX concentrate 50-70 units/kg <15 yrs  
The dosage for recombinant factor IX is substantially higher because of its lower recovery, particularly in children.

**Von Willebrand Disease:**  
Type 1 and Type 2A or 2B known to have used desmopressin safely and effectively – (Octostim/DDAVP) 0.3 mcg/kg (max. 20 mcg) –SC/IV

For patients not responding to desmopressin (such as Type 3 or Type 2B) use a VW factor concentrate containing factor VIII such as Humate-P 60-80 Ristocetin cofactor units/kg

**For mucosal bleeds in all above add:**  
Tranexamic Acid (Cyklokapron) 25 mg/kg po tid 1-7 days (contraindicated if hematuria)

**Dosages are patient specific – these are general guidelines only. Round doses up to the nearest vial. If the products listed are not available, please call the nearest Canadian Blood Services or Héma-Québec Centre.**

For more detailed guidelines on emergency hemophilia care please consult:  
[www.hemophilia.ca/emergency](http://www.hemophilia.ca/emergency)



**HEMOPHILIA TREATMENT CENTRE:**